Interim FDG-PET Scan in Hodgkin's Lymphoma: Hopes and Caveats - Wikidata - awgldk - TriplyDB

Interim FDG-PET Scan in Hodgkin's Lymphoma: Hopes and Caveats

Interim FDG-PET Scan in Hodgkin's Lymphoma: Hopes and Caveats

http://www.wikidata.org/entity/Q34475763

about

FDG-PET/CT based response-adapted treatment.Positron emission tomographic scans in lymphoma: convention and controversy.Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone?Circulating MicroRNAs as Biomarkers in Diffuse Large B-cell Lymphoma: A Pilot Prospective Longitudinal Clinical Study.

P2860

Q36286595-2117A1C6-633E-4489-991A-15ED19F5A733 Q36399538-8B3476D8-4E97-4E79-848A-FC78736D6EA8 Q44635336-7018CD0A-558C-43FC-A3AA-F2D63953DAB4 Q55515075-C2350D24-2419-4C84-BD13-1346C23A3C73

P2860

Interim FDG-PET Scan in Hodgkin's Lymphoma: Hopes and Caveats

http://www.wikidata.org/entity/Q34475763

description

2010 nî lūn-bûn

@nan

2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Interim FDG-PET Scan in Hodgkin's Lymphoma: Hopes and Caveats

@ast

Interim FDG-PET Scan in Hodgkin's Lymphoma: Hopes and Caveats

@en

Interim FDG-PET Scan in Hodgkin's Lymphoma: Hopes and Caveats

@nl

type

label

Interim FDG-PET Scan in Hodgkin's Lymphoma: Hopes and Caveats

@ast

Interim FDG-PET Scan in Hodgkin's Lymphoma: Hopes and Caveats

@en

Interim FDG-PET Scan in Hodgkin's Lymphoma: Hopes and Caveats

@nl

prefLabel

Interim FDG-PET Scan in Hodgkin's Lymphoma: Hopes and Caveats

@ast

Interim FDG-PET Scan in Hodgkin's Lymphoma: Hopes and Caveats

@en

Interim FDG-PET Scan in Hodgkin's Lymphoma: Hopes and Caveats

@nl

P1433

Q34475763-A7C0381D-7D75-4CBF-974E-05C85568E567

P1476

Q34475763-3EFE6FAD-5718-430A-B250-C8DD15641153

P2093

Q34475763-83CA1E0E-CE00-4718-A815-8DBF16AD1DFA

Q34475763-A50B651A-CD2E-4140-852B-EE21212E1D73

Q34475763-D3F3001E-E1AE-4F40-91DD-054217BE31AD

P2860

Q34475763-0199355E-E3C9-4C4C-AA18-E02E91725693

Q34475763-030ADA85-2228-4D16-8E17-7C415284838A

Q34475763-07DF088D-EDEC-47C4-B3FD-DF7341C9A5D1

Q34475763-0A89CC66-82DF-49CC-88E2-B36CAB844711

Q34475763-0E91F7BA-FFB8-4B4F-A707-39D03B036934

Q34475763-127B589C-5971-4B78-9611-4E4A9749A32A

Q34475763-1ADBFCE2-D56C-41A5-9EAA-22D59C05BE66

Q34475763-1DE439E9-07D8-4641-8268-F3B3473C800B

Q34475763-2D645001-680D-4CB4-82BF-88A31D8AF9AB

Q34475763-4008454F-67E4-4D63-B4DC-322543E8E7F7

P304

Q34475763-C695ECF3-846B-4FF0-9E02-0B7B8D50844A

P31

Q34475763-44657708-EB26-4D78-B075-1D1C4059CABD

P356

Q34475763-583884B3-E499-421C-843B-749D74CF2CF2

P478

Q34475763-7B4940A6-A7A4-4796-BBE9-CA04D88984A8

P577

Q34475763-DABC5C7F-75C6-4254-9800-DDD880B54BF8

P5875

Q34475763-2A1E1ABA-D2E4-41EC-B93A-D04BB6E4D629

P698

Q34475763-9C588233-7B51-4D23-BA66-F30785850CB6

P932

Q34475763-3BA174C1-1156-4978-99FF-AA4598EF0575

P356

P1433

Advances in Hematology

P1476

Interim FDG-PET Scan in Hodgkin's Lymphoma: Hopes and Caveats

@en

P2093

A Bosly

http://www.w3.org/2001/XMLSchema#string

M André

http://www.w3.org/2001/XMLSchema#string

T Vander Borght

http://www.w3.org/2001/XMLSchema#string

P2860

A functional dynamic scoring model to elucidate the significance of post-induction interim fluorine-18-fluorodeoxyglucose positron emission tomography findings in patients with Hodgkin's lymphoma.

Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease.

Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.

Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.

Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.

Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.

Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials.

Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma.

2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas.

The role of FDG-PET scans in patients with lymphoma.

P304

430679

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2011/430679

http://www.w3.org/2001/XMLSchema#string

P478

2011

http://www.w3.org/2001/XMLSchema#string

P577

2010-12-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49754571

http://www.w3.org/2001/XMLSchema#string

P698

21234093

http://www.w3.org/2001/XMLSchema#string

P932

3017950

http://www.w3.org/2001/XMLSchema#string